(Q37323609)

19 August 2017

1 reference

title

Management of aggressive pituitary adenomas: current treatment strategies (English)

1 reference

19 August 2017

Michael Buchfelder

1

1 reference

19 August 2017

publication date

1 January 2009

1 reference

19 August 2017

1 reference

19 August 2017

volume

12

1 reference

19 August 2017

issue

3

1 reference

19 August 2017

page(s)

256-260

1 reference

https://scigraph.springernature.com/pub.10.1007/s11102-008-0153-z

19 August 2017

exact match

0 references

cites work

Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly.

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11102-008-0153-Z

Clinical review: The antitumoral effects of somatostatin analog therapy in acromegaly

21 January 2018

1 reference

12 December 2020

Long-term and low-dose treatment with cabergoline induces macroprolactinoma shrinkage

1 reference

12 December 2020

Role of medical therapy in the management of acromegaly.

1 reference

12 December 2020

Treatment of macroprolactinoma with cabergoline: a study of 85 patients

1 reference

12 December 2020

One-year follow-up of patients with acromegaly treated with fixed or titrated doses of lanreotide Autogel

1 reference

12 December 2020

A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline Comparative Study Group

1 reference

12 December 2020

Long-term response of pituitary carcinoma to temozolomide. Report of two cases.

1 reference

12 December 2020

Antitumour effects of temozolomide in a man with a large, invasive prolactin-producing pituitary neoplasm

1 reference

12 December 2020

Long-term (up to 18 years) effects on GH/IGF-1 hypersecretion and tumour size of primary somatostatin analogue (SSTa) therapy in patients with GH-secreting pituitary adenoma responsive to SSTa.

1 reference

12 December 2020

Temozolomide: a novel treatment for pituitary carcinoma

1 reference

12 December 2020

Control of pituitary adenoma cell proliferation by somatostatin analogs, dopamine agonists and novel chimeric compounds

1 reference

12 December 2020

Temozolomide therapy in a man with an aggressive prolactin-secreting pituitary neoplasm: Morphological findings

1 reference

12 December 2020

MGMT immunoexpression predicts responsiveness of pituitary tumors to temozolomide therapy

1 reference

12 December 2020

Surgical treatment of giant pituitary adenomas: strategies and results in a series of 95 consecutive patients

1 reference

12 December 2020

Surgical debulking of pituitary macroadenomas causing acromegaly improves control by lanreotide

1 reference

12 December 2020

Temozolomide in the treatment of an invasive prolactinoma resistant to dopamine agonists

1 reference

12 December 2020

Predictors of tumor shrinkage after primary therapy with somatostatin analogs in acromegaly: a prospective study in 99 patients

1 reference

12 December 2020

Macroprolactinoma shrinkage during cabergoline treatment is greater in naive patients than in patients pretreated with other dopamine agonists: a prospective study in 110 patients

1 reference

12 December 2020

Treatment of prolactin-secreting macroadenomas with the once-weekly dopamine agonist cabergoline

1 reference

12 December 2020

Lanreotide 60 mg, a longer-acting somatostatin analog: tumor shrinkage and hormonal normalization in acromegaly.

1 reference

12 December 2020

Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients

1 reference

12 December 2020

A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR (long-acting repeatable octreotide) in the primary therapy of patients with acromegaly

1 reference

12 December 2020

Advances in the treatment of prolactinomas

1 reference

12 December 2020

10.1007/S11102-008-0153-Z

Identifiers

DOI

1 reference

19 August 2017

1 reference